Skip to contentG
Goldenwell Biotech, Inc.
G
GWLLGoldenwell Biotech, Inc. Q1 2025 · 10-Q
Revenue$0.00$0.00−100.0% vs Q1 2024 Net Income-$38.54K-$38.54KN/M vs Q1 2024 EPS Diluted$0.00$0.00— vs Q1 2024 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Goldenwell Biotech, Inc. · CIK 1800373 · Engraved from SEC EDGAR
-$36,436
N/M
Operating Cash Flow-$32,276N/M ended Mar 31, 2025 · filed May 27, 2025 · 57 d after period end